Nearly 20 million new cancer cases were diagnosed worldwide in 2022, according to the most recent data from the International Agency for Research on Cancer (IARC). That same year, close to 10 million people died from the disease, making cancer responsible for roughly one in six deaths globally.
How Many People Are Diagnosed Each Year
The precise figure from GLOBOCAN 2022 is 19,976,499 new cases across all cancer types, both sexes, and all ages. That number reflects diagnoses in a single year, not the total number of people currently living with cancer, which is substantially higher when you account for everyone still undergoing treatment or in remission from prior years.
Children and adolescents make up a small but significant portion: about 400,000 new cases each year among those aged 0 to 19. The vast majority of cancer diagnoses occur in adults over 50, driven by decades of accumulated cellular damage and longer exposure to risk factors like tobacco, alcohol, obesity, and environmental pollutants.
The Most Deadly Cancers
Cancer killed nearly 10 million people in 2022. To put that in perspective, cancer alone accounts for more deaths than HIV/AIDS, malaria, and tuberculosis combined. Lung cancer remains the leading cause of cancer death worldwide, followed by colorectal, liver, stomach, and breast cancers. These five types together drive the majority of cancer mortality globally.
Survival Varies Dramatically by Country
Where you live has an enormous impact on your chances of surviving cancer. Five-year survival rates for breast cancer, for example, reach about 90% in the United States and Australia but drop to 66% in India. For childhood leukemia, the gap is even more striking: five-year survival ranges from under 50% in Ecuador to over 95% in Finland.
The pattern holds across cancer types but shifts by region in interesting ways. Southeast Asian countries lead the world in survival for several gastrointestinal cancers. South Korea reports five-year survival rates near 69% for stomach cancer and 72% for colon cancer. Japan leads for esophageal cancer at 36%, and Taiwan for liver cancer at about 28%. These numbers reflect decades of investment in screening programs tailored to regionally common cancers.
Meanwhile, countries with the highest overall survival rates cluster in North America, Western Europe, Australia, and New Zealand. The common thread is access to early detection, timely treatment, and well-resourced healthcare systems. In lower-income countries, a cancer diagnosis is far more likely to be fatal. Research across African nations found a strong inverse relationship between a country’s development level and its cancer death-to-diagnosis ratio. In wealthier nations, more people survive relative to how many are diagnosed. In poorer nations, that ratio flips sharply.
The Economic Toll
Cancer’s cost extends well beyond hospital bills. In 2022, premature cancer deaths cost the global economy an estimated $566 billion in lost productivity, equivalent to 0.6% of the world’s entire GDP. About $305 billion of that came from lost paid work, while $260 billion reflected unpaid contributions like caregiving and household labor that are rarely counted in economic analyses. If the calculation accounts for people who would have worked past 65 (as is increasingly common), that figure jumps to $904 billion.
These numbers capture only the losses from people who died. They don’t include the productivity lost by the millions of people currently undergoing treatment, recovering from surgery, or managing long-term side effects that prevent them from working at full capacity.
Why the Numbers Are Expected to Rise
The World Health Organization projects over 35 million new cancer cases per year by 2050, a 77% increase from 2022 levels. Several forces are driving this trajectory simultaneously. The global population is aging, and cancer risk rises with age. Obesity rates are climbing in nearly every region. Alcohol consumption is spreading into populations that previously had low intake. Air pollution continues to worsen in rapidly industrializing nations.
At the same time, improvements in detection mean more cancers are being found that previously would have gone undiagnosed, particularly in countries expanding access to screening. This is a paradox of progress: better healthcare infrastructure leads to higher reported incidence even as it also improves survival. The projected increase to 35 million cases reflects both a genuine rise in cancer occurrence and an expansion of the world’s ability to detect it.
Low- and middle-income countries will bear a disproportionate share of this growth. Many of these nations are simultaneously dealing with rising cancer rates and a lack of the treatment infrastructure needed to manage them, creating a widening gap between diagnosis and the capacity to deliver effective care.